{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T14:45:28Z","timestamp":1782571528654,"version":"3.54.5"},"reference-count":94,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071413"],"award-info":[{"award-number":["82071413"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Gene therapy using the adeno-associated virus (rAAV) to deliver mini\/micro- dystrophin is the current promising strategy for Duchenne Muscular Dystrophy (DMD). However, the further transformation of this strategy still faces many \u201cbottlenecks\u201d. Most gene therapies are only suitable for infants with strong muscle cell regeneration and immature immune system, and the treatment depends heavily on the high dose of rAAV. However, high-dose rAAV inevitably causes side effects such as immune response and acute liver toxicity. Therefore, how to reduce the degree of fibrosis and excessive immune response in older patients and uncouple the dependence association between therapeutic effect and high dose rAAV are crucial steps for the transformation of rAAV-based gene therapy. The article analyzes the latest research and finds that the application of utrophin, the homologous protein of dystrophin, could avoid the immune response associated with dystrophin, and the exploration of methods to improve the expression level of mini\/micro-utrophin in striated muscle, combined with the novel MyoAAV with high efficiency and specific infection of striated muscle, is expected to achieve the same therapeutic efficacy under the condition of reducing the dose of rAAV. Furthermore, the delivery of allogeneic cardio sphere-derived cells (CDCs) with anti-inflammatory and anti-fibrotic characteristics combined with immune suppression can provide a continuous and appropriate \u201cwindow period\u201d for gene therapy. This strategy can expand the number of patients who could benefit from gene therapy.<\/jats:p>","DOI":"10.3390\/genes13112021","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T04:49:20Z","timestamp":1667450960000},"page":"2021","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Strategies for Bottlenecks of rAAV-Mediated Expression in Skeletal and Cardiac Muscle of Duchenne Muscular Dystrophy"],"prefix":"10.3390","volume":"13","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[{"name":"School of Sports Science, Beijing Sport University, Beijing 100084, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafeng","family":"Song","sequence":"additional","affiliation":[{"name":"China Institute of Sport and Health Science, Beijing Sport University, Beijing 100084, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/BF00275183","article-title":"Duchenne muscular dystrophy: Pathogenetic aspects and genetic prevention","volume":"66","author":"Moser","year":"1984","journal-title":"Hum. Genet."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1378\/chest.07-0458","article-title":"American College of Chest Physicians consensus statement on the respiratory and related management of patients with Duchenne muscular dystrophy undergoing anesthesia or sedation","volume":"132","author":"Birnkrant","year":"2007","journal-title":"Chest"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/355696a0","article-title":"Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix","volume":"355","author":"Ervasti","year":"1992","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/mus.23807","article-title":"The cooperative international neuromuscular research group Duchenne natural history study\u2014A longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used","volume":"48","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/0092-8674(95)90344-5","article-title":"Three muscular dystrophies: Loss of cytoskeleton-extracellular matrix linkage","volume":"80","author":"Campbell","year":"1995","journal-title":"Cell"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Matthews, E., Brassington, R., Kuntzer, T., Jichi, F., and Manzur, A.Y. (2016). Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst. Rev.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states","volume":"13","author":"Cohn","year":"2007","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jacc.2004.09.078","article-title":"Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy","volume":"45","author":"Duboc","year":"2005","journal-title":"J. Am. Coll Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/nat.2016.0657","article-title":"FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga","volume":"27","author":"Krieg","year":"2017","journal-title":"Nucleic. Acid Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/nrneurol.2016.180","article-title":"Eteplirsen therapy for Duchenne muscular dystrophy: Skipping to the front of the line","volume":"12","author":"Dowling","year":"2016","journal-title":"Nat. Rev. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: The physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1089\/hum.2020.286","article-title":"Lack of Toxicity in Nonhuman Primates Receiving Clinically Relevant Doses of an AAV9.U7snRNA Vector Designed to Induce Exon 2 Skipping","volume":"32","author":"Gushchina","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_19","first-page":"1346","article-title":"Absence of Significant Off-Target Splicing Variation with a U7snRNA Vector Targeting Exon 2 Duplications","volume":"32","author":"Wein","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_20","unstructured":"(2022, October 27). Clinicaltrials.gov. AAV9 U7snRNA Gene Therapy to Treat Boys with DMD Exon 2 Duplications, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04240314."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.ymthe.2021.09.026","article-title":"Genome editing in large animal models","volume":"29","author":"Maynard","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split-Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic. Acids Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41591-019-0738-2","article-title":"Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy","volume":"26","author":"Moretti","year":"2020","journal-title":"Nat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-Associated Virus (AAV) as a Vector for Gene Therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12686","DOI":"10.1128\/JVI.05359-11","article-title":"The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes","volume":"85","author":"Sonntag","year":"2011","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/343180a0","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wilton-Clark, H., and Yokota, T. (2022). Antisense and Gene Therapy Options for Duchenne Muscular Dystrophy Arising from Mutations in the N-Terminal Hotspot. Genes, 13.","DOI":"10.3390\/genes13020257"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol. Ther."},{"key":"ref_31","first-page":"1122","article-title":"Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial","volume":"77","author":"Mendell","year":"2020","journal-title":"J. AMA. Neurol."},{"key":"ref_32","unstructured":"Sarepta Therapeutics, I. (2022, October 12). Sarepta Therapeutics\u2019 Investigational Gene Therapy SRP-9001 for Duchenne Muscular Dystrophy Demonstrates Significant Functional Improvements Across Multiple Studies. Available online: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-investigational-gene-therapy-srp-9001."},{"key":"ref_33","unstructured":"Sarepta Therapeutics, I. (2022, October 05). Sarepta Therapeutics Announces Top-Line Results for Part 1 of Study 102 Evaluating SRP-9001, Its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy. Available online: https:\/\/investorrelations.Sarepta.com\/news-releases\/news-release-details\/Sarepta-therapeutics-announces-top-line-results-part-1-study-102."},{"key":"ref_34","unstructured":"(2022, October 05). Clinicaltrials.gov. A Gene Transfer Therapy Study to Evaluate the Safety of and Expression from SRP-9001 in Participants with Duchenne Muscular Dystrophy (DMD), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04626674."},{"key":"ref_35","unstructured":"Zaidman, C.P.C., Mcdonald, C., Giblin, K., Collins, L., Wang, S., Upadhyay, S., Lewis, S., Malhotra, J., and Griffin, D.A. (2022, October 07). ENDEAVOR: A Gene Delivery Study to Evaluate the Safety of and Expression from SRP-9001 in Duchenne Muscular Dystrophy. Available online: https:\/\/investorrelations.sarepta.com\/static-files\/a674d68e-823c-43a4-b26c-e6bfc6a5a95b."},{"key":"ref_36","unstructured":"Sarepta Therapeutics, I. (2022, October 07). Sarepta Therapeutics\u2019 SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne. Available online: https:\/\/investorrelations.Sarepta.com\/news-releases\/news-release-details\/Sareptatherapeutics-SRP-9001-shows-sustained-functional."},{"key":"ref_37","unstructured":"(2022, October 05). Clinicaltrials.gov. A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of SRP-9001 in Participants with Duchenne Muscular Dystrophy (DMD), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05096221."},{"key":"ref_38","unstructured":"(2022, October 27). Clinicaltrials.gov. Pfizer\u2019s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study, Available online: https:\/\/investors.pfizer.com\/investor-news\/press-releasedetails\/2020\/Pfizers-New-Phase-1b-Results-of-Gene-Therapy-in-Ambulatory-Boys-with-Duchenne-Muscular-DystrophyDMD-Support-Advancement-into-Pivotal-Phase-3-Study\/default.aspx."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/gt.2008.104","article-title":"Construction and analysis of compact muscle-specific promoters for AAV vectors","volume":"15","author":"Wang","year":"2008","journal-title":"Gene Ther."},{"key":"ref_40","unstructured":"(2021, December 09). Safety and Efficacy of pf-06939926 Gene Therapy in Boys with Duchenne Muscular Dystrophy: Update on Data from the Phase 1b Study | Mda Clinical & Scientific Conference 2022. Available online: https:\/\/mdaconference.org\/index.php\/node\/1168."},{"key":"ref_41","unstructured":"(2022, October 05). Clinicaltrials.gov. A Phase 3 Study to Evaluate the Safety and Efficacy of pf-06939926 for the Treatment of Duchenne Muscular Dystrophy, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04281485."},{"key":"ref_42","unstructured":"Biotech, F. (2022, October 05). Pfizer Tightens DMD Patient Criteria after Serious Adverse Events Crop up in Phase 3 Gene Therapy Trial | Fiercebiotech. Available online: https:\/\/www.fiercebiotech.com\/biotech\/pfizer-tightening-Duchenne-muscular-dystrophy-phase-3-criteriaadverse-event\/."},{"key":"ref_43","unstructured":"Biotech, F. (2022, October 05). Pfizer Reports Patient Death in Early-Stage Duchenne Gene Therapy Trial, Halts Enrollment. Available online: https:\/\/www.fiercebiotech.com\/biotech\/pfizer-reports-death-patient-Duchenne-trial-halts-enrolment."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.ymthe.2018.07.011","article-title":"Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy","volume":"26","author":"Duan","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_45","unstructured":"BioSpace (2022, October 06). FDA Slaps Clinical Hold on Solid Bioscience DMD Gene Therapy Program. Available online: https:\/\/www.biospace.com\/article\/fda-slaps-clinical-hold-on-solid-bioscience-DMD-gene-therapy-program\/."},{"key":"ref_46","unstructured":"BioSpace (2022, October 07). FDA Slaps Second Clinical Hold on Solid Biosciences\u2019 DMD Gene Therapy Due to Adverse Event. Available online: https:\/\/www.biospace.com\/article\/fda-slaps-second-clinical-hold-on-solid-biosciences-DMD-gene-therapy-due-toadverse-events\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement is an essential component of the immune response to adeno-associated virus vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J. Virol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e1852","DOI":"10.1212\/WNL.0000000000007319","article-title":"X-linked myotubular myopathy: A prospective international natural history study","volume":"92","author":"Annoussamy","year":"2019","journal-title":"Neurology."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1089\/hum.2022.29216.bfs","article-title":"Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coviro.2016.07.006","article-title":"Systemic delivery of adeno-associated viral vectors","volume":"21","author":"Duan","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/mt.2010.124","article-title":"Recognition of virus infection and innate host responses to viral gene therapy vectors","volume":"18","author":"Shayakhmetov","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_57","first-page":"706","article-title":"Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice","volume":"3","author":"Petrof","year":"1996","journal-title":"Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/NEN.0b013e3181e9a34b","article-title":"Targeting fibrosis in Duchenne muscular dystrophy","volume":"69","author":"Zhou","year":"2010","journal-title":"J. Neuropathol Exp. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/NEN.0b013e3181aa31c2","article-title":"Endomysial fibrosis in Duchenne muscular dystrophy: A marker of poor outcome associated with macrophage alternative activation","volume":"68","author":"Desguerre","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1006\/mthe.1999.0019","article-title":"Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer","volume":"1","author":"Cordier","year":"2000","journal-title":"Mol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"eabn4704","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"Tulalamba","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/339055a0","article-title":"An autosomal transcript in skeletal muscle with homology to dystrophin","volume":"339","author":"Love","year":"1989","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0960-8966(91)90023-L","article-title":"Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle","volume":"1","author":"Khurana","year":"1991","journal-title":"Neuromuscul. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0960-8966(94)90070-1","article-title":"Expression of dystrophin-associated glycoproteins during human fetal muscle development: A preliminary immunocytochemical study","volume":"4","author":"Matsumura","year":"1994","journal-title":"Neuromuscul. Disord."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneuroim.2003.11.013","article-title":"Thymic myoid cells express high levels of muscle genes","volume":"148","author":"Bismuth","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/hmg\/1.2.103","article-title":"Characterization of a 4.8kb transcript from the Duchenne muscular dystrophy locus expressed in Schwannoma cells","volume":"1","author":"Blake","year":"1992","journal-title":"Hum. Mol. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1042\/bj2870755","article-title":"Evolutionary conservation of the dystrophin central rod domain","volume":"287","author":"Sherratt","year":"1992","journal-title":"Biochem. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/360591a0","article-title":"Primary structure of dystrophin-related protein","volume":"360","author":"Tinsley","year":"1992","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/384349a0","article-title":"Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene","volume":"384","author":"Tinsley","year":"1996","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1006\/bbrc.1997.7936","article-title":"Efficient utrophin expression following adenovirus gene transfer in dystrophic muscle","volume":"242","author":"Gilbert","year":"1998","journal-title":"Biochem Biophys Res. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/mt.2008.149","article-title":"Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin\/utrophin-deficient mice","volume":"16","author":"Odom","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/sj.gt.3301941","article-title":"Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer","volume":"10","author":"Cerletti","year":"2003","journal-title":"Gene Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/352536a0","article-title":"The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy","volume":"352","author":"Stedman","year":"1991","journal-title":"Nature"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"17337","DOI":"10.1073\/pnas.0607015103","article-title":"Small dsRNAs induce transcriptional activation in human cells","volume":"103","author":"Li","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.1158\/0008-5472.CAN-12-1871","article-title":"Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth","volume":"72","author":"Kang","year":"2012","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/d41573-021-00127-2","article-title":"Small activating RNAs lead the charge to turn up gene expression","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5961","DOI":"10.1158\/1078-0432.CCR-21-0986","article-title":"Upregulation of C\/EBP\u03b1 Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer","volume":"27","author":"Hashimoto","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrg3645","article-title":"Ribosome profiling: New views of translation, from single codons to genome scale","volume":"15","author":"Ingolia","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0092-8674(86)90762-2","article-title":"Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes","volume":"44","author":"Kozak","year":"1986","journal-title":"Cell"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1093\/nar\/9.20.5233","article-title":"Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes","volume":"9","author":"Kozak","year":"1981","journal-title":"Nucleic. Acids Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1038\/s41467-021-24436-7","article-title":"High-throughput 5\u2019 UTR engineering for enhanced protein production in non-viral gene therapies","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"13351","DOI":"10.1038\/s41598-018-31569-1","article-title":"Cardiosphere-derived cells suppress allogeneic lymphocytes by production of PGE2 acting via the EP4 receptor","volume":"8","author":"Dutton","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(12)60195-0","article-title":"Intracoronary cardiosphere-derived cel.lls for heart regeneration after myocardial infarction (CADUCEUS): A prospective, randomised phase 1 trial","volume":"379","author":"Makkar","year":"2012","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jacc.2013.08.724","article-title":"Intracoronary cardiosphere-derived cells after myocardial infarction: Evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction)","volume":"63","author":"Malliaras","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","article-title":"Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"McDonald","year":"2022","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.stemcr.2018.01.023","article-title":"Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy","volume":"10","author":"Aminzadeh","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Rogers, R.G., Fournier, M., Sanchez, L., Ibrahim, A.G., Aminzadeh, M.A., Lewis, M.I., and Marb\u00e1n, E. (2019). Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice. JCI Insight, 4.","DOI":"10.1172\/jci.insight.125754"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"658038","DOI":"10.3389\/fimmu.2021.658038","article-title":"Immunomodulation in Administration of rAAV: Preclinical and Clinical Adjuvant Pharmacotherapies","volume":"12","author":"Chu","year":"2021","journal-title":"Front. Immunol"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/11\/2021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:09:50Z","timestamp":1760144990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/13\/11\/2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":94,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["genes13112021"],"URL":"https:\/\/doi.org\/10.3390\/genes13112021","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}